Cervical Dystonia Therapeutics Market by Product and Geography - Forecast and Analysis 2021-2025

***1. Executive Summary                           

                **1.1     Market Overview            

                                *Exhibit 01:  Key Finding 1

                                *Exhibit 02:  Key Finding 2

                                *Exhibit 03:  Key Finding 3

                                *Exhibit 04:  Key Finding 5

                                *Exhibit 05:  Key Finding 6

                                *Exhibit 06:  Key Finding 7

                                *Exhibit 07:  Key Finding 8

***2. Market Landscape              

                **2.1 Market ecosystem           

                                *2.1.1 Parent Market

                                *Exhibit 08:  Parent market

                                *Exhibit 09:  Market characteristics

                **2.2 Value Chain Analysis          

                                *Exhibit 10:  Value Chain Analysis: Pharmaceuticals

                                *2.2.1    Research and development (R&D) and drug discovery

                                *2.2.2    Integration and product development

                                *2.2.3    Manufacturing

                                *2.2.4    Outbound logistics

                                *2.2.5    Marketing and sales

                                *2.2.6    Support services

                             *2.2.7   Innovation

***3. Market Sizing                       

                **3.1 Market definition

                                *Exhibit 11:  Offerings of vendors included in the market definition

                **3.2 Market segment analysis 

                                *Exhibit 12:  Market segments

                **3.3 Market size 2021 

                **3.4 Market outlook: Forecast for 2020 - 2025 

                                *3.4.1Estimating growth rates for emerging and high-growth markets

                                *3.4.2Estimating growth rates for mature markets

                                *Exhibit 13:  Global - Market size and forecast 2020 - 2025 ($ million)

                                *Exhibit 14:  Global market: Year-over-year growth 2020 - 2025 (%)

***4. Five Forces Analysis                          

                **4.1 Five Forces Summary        

                                *Exhibit 15:  Five forces analysis 2020 & 2025

                **4.2 Bargaining power of buyers           

                                *Exhibit 16: Bargaining power of the buyer

                **4.3 Bargaining power of suppliers       

                                *Exhibit 17: Bargaining power of the supplier

                **4.4 Threat of new entrants    

                                *Exhibit 18: Threat of new entrants

                **4.5 Threat of substitutes         

                                *Exhibit 19: Threat of substitutes

                **4.6 Threat of rivalry   

                                *Exhibit 20: Threat of rivalry

                **4.7 Market condition

                                *Exhibit 21: Market condition - Five forces 2020

***5. Market Segmentation by Product

              **5.1 Market segments

                                *Exhibit 22:  Product- Market share 2020-2025 (%)

                **5.2 Comparison by Product    

                                *Exhibit 23:  Comparison by Product

                **5.3 Botulinum toxins - Market size and forecast 2020-2025       

                                *Exhibit 24:  Botulinum toxins - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 25:  Botulinum toxins - Year-over-year growth 2020-2025 (%)

                **5.4 Other therapeutics - Market size and forecast 2020-2025   

                                *Exhibit 26:  Other therapeutics - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 27:  Other therapeutics - Year-over-year growth 2020-2025 (%)

                **5.5 Market opportunity by Product    

                                *Exhibit 28:  Market opportunity by Product

***6. Customer landscape                         

                                *Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria

                **6.1 Overview

                                *Exhibit 29:  Customer landscape

***7. Geographic Landscape                     

                **7.1 Geographic segmentation

                                *Exhibit 30:  Market share by geography 2020-2025 (%)

                **7.2 Geographic comparison   

                                *Exhibit 31:  Geographic comparison

                **7.3 North America - Market size and forecast 2020-2025           

                                *Exhibit 32:  North America - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 33:  North America - Year-over-year growth 2020-2025 (%)

                **7.4 Europe - Market size and forecast 2020-2025          

                                *Exhibit 34:  Europe - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 35:  Europe - Year-over-year growth 2020-2025 (%)

                **7.5 Asia - Market size and forecast 2020-2025

                                *Exhibit 36:  Asia - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 37:  Asia - Year-over-year growth 2020-2025 (%)

                **7.6 ROW- Market size and forecast 2020-2025               

                                *Exhibit 38:  ROW - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 39:  ROW - Year-over-year growth 2020-2025 (%)

                **7.7 Key leading countries        

                                *Exhibit 40:  Key leading countries

                **7.8 Market opportunity by geography

                                *Exhibit 41:  Market opportunity by geography ($ million)

***8. Drivers, Challenges, and Trends                   

                **8.1 Market drivers     

                                *8.1.1    Expected approval of late-stage pipeline molecules

                                *8.1.2    Increasing awareness about cervical dystonia

                                *8.1.3    Rising middle-age group population

                **8.2 Market challenges              

                                *8.2.1    Availability of alternate therapies

                                *8.2.2    Side effects associated with the available medications

                                *8.2.3    High cost of first-line treatment medicines

                                *Exhibit 42:  Impact of drivers and challenges

                **8.3 Market trends      

                                *8.3.1    Reimbursement for botulinum neurotoxin injections

                                *8.3.2    Strategic alliances

                                *8.3.3    Biosimilars development for cervical dystonia

***9. Vendor Landscape                             

                **9.1 Overview

                                *Exhibit 43:  Vendor landscape

                **9.2 Landscape disruption        

                                *Exhibit 44:  Landscape disruption

                                *Exhibit 45: Industry Risk

                **9.3 Competitive Scenario        

***10. Vendor Analysis               

                **10.1 Vendors covered              

                                *Exhibit 46: Vendors covered

                **10.2 Market positioning of vendors    

                                *Exhibit 47: ?Market positioning of vendors?

                **10.3 AbbVie Inc.         

                                *Exhibit 48:  AbbVie Inc. - Overview

                                *Exhibit 49:  AbbVie Inc. - Business segments

                                *Exhibit 50:  AbbVie Inc. - Key offerings

                                *Exhibit 51:  AbbVie Inc. - Segment focus

                *10.4 Akorn Inc.

                                *Exhibit 52:  Akorn Inc. - Overview

                                *Exhibit 53:  Akorn Inc. - Product and service

                                *Exhibit 54:  Akorn Inc. - Key offerings

                                *Exhibit 55:  Akron Inc. – Key news

                *10.5 Eisai Co. Ltd.

                                *Exhibit 56:  Eisai Co. Ltd. - Overview

                                *Exhibit 57:  Eisai Co. Ltd. - Business segments

                                *Exhibit 58:  Eisai Co. Ltd. - Key offerings

                                *Exhibit 59:  Eisai Co. Ltd. - Segment focus

                **10.6 Galderma SA      

                                *Exhibit 60:  Galderma SA - Overview

                                *Exhibit 61:  Galderma SA - Product and service

                                *Exhibit 62:  Galderma SA - Key offerings

                **10.7 Ipsen Pharma     

                                *Exhibit 63:  Ipsen Pharma  - Overview

                                *Exhibit 64:  Ipsen Pharma  - Business segments

                                *Exhibit 65:  Ipsen Pharma  - Key offerings

                                *Exhibit 66:  Ipsen Pharma  - Segment focus

                **10.8 Lannett Co. Inc. 

                                *Exhibit 67:  Lannett Co. Inc. - Overview

                                *Exhibit 68:  Lannett Co. Inc. - Business segments

                                *Exhibit 69:  Lannett Co. Inc. - Key offerings

                                *Exhibit 70:  Lannett Co. Inc. - Segment focus

                **10.9 Medytox Inc.      

                                *Exhibit 71:  Medytox Inc. - Overview

                                *Exhibit 72:  Medytox Inc. - Business segments

                                *Exhibit 73:  Medytox Inc. - Key offerings

                                *Exhibit 74:  Medytox Inc. - Segment focus

                **10.10 Merz Pharma GmbH and Co. KGaA         

                                *Exhibit 75:  Merz Pharma GmbH and Co. KGaA - Overview

                                *Exhibit 76:  Merz Pharma GmbH and Co. KGaA - Product and service

                                *Exhibit 77:  Merz Pharma GmbH and Co. KGaA - Key offerings

                **10.11 Revance Therapeutics Inc.         

                                *Exhibit 78:  Revance Therapeutics Inc. - Overview

                                *Exhibit 79:  Revance Therapeutics Inc. - Product and service

                                *Exhibit 80:  Revance Therapeutics Inc. - Key offerings

                **10.12 Supernus Pharmaceuticals Inc. 

                                *Exhibit 81:  Supernus Pharmaceuticals Inc. - Overview

                                *Exhibit 82:  Supernus Pharmaceuticals Inc. - Business segments

                                *Exhibit 83:  Supernus Pharmaceuticals Inc. – Key news

                                *Exhibit 84:  Supernus Pharmaceuticals Inc. - Key offerings

                                *Exhibit 85:  Supernus Pharmaceuticals Inc. - Segment focus

***11. Appendix                            

                **11.1 Scope of the report         

                                *11.1.1 ????Market definition

                                *11.1.2 ????Objectives

                                *11.1.3 ????Notes and caveats

                **11.2 Currency conversion rates for US$            

                                *Exhibit 86: ?Currency conversion rates for US$?

                **11.3 Research Methodology 

                                *Exhibit 87: ?Research Methodology

                                *Exhibit 88: ??Validation techniques employed for market sizing?

                                *Exhibit 89: ??Information sources

                **11.4 List of abbreviations        

                                *Exhibit 90: List of abbreviations